<?xml version="1.0" encoding="UTF-8"?>
<STUDY_SET xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <STUDY center_name="San Diego State University" alias="Cystic Fibrosis Viral Metagenomic Studies" accession="SRP007749">
    <IDENTIFIERS>
      <PRIMARY_ID>SRP007749</PRIMARY_ID>
      <EXTERNAL_ID namespace="BioProject" label="primary">PRJNA71831</EXTERNAL_ID>
      <SUBMITTER_ID namespace="San Diego State University">Cystic Fibrosis Viral Metagenomic Studies</SUBMITTER_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Viral and Microbial Cystic Fibrosis Lung Metagenome</STUDY_TITLE>
      <STUDY_TYPE existing_study_type="Metagenomics"/>
      <STUDY_ABSTRACT>CF patients undergo recurrent pulmonary exacerbations. Prognosis and     treatment regimes are entirely based on clinical examinations and culture     results. Patients are typically treated with a common set of IV antibiotics     during pulmonary exacerbations. In addition to the improvement in lung     function, the eradication of 201C pathogenic 201D microbes based on microbe-targeted     assays serves as an indicator of recovery. However, there is often little     correlation between the beneficial outcome and the clearance of the     infection. The goal of this study is to generate a set of metagenomes and     metatranscriptomes from each patient to characterize the microbial and viral     communities in CF lungs associated with different perturbations, such as     during exacerbations and following antibiotic treatments.   Expectorated sputum samples were collected from Cystic Fibrosis individuals.</STUDY_ABSTRACT>
      <CENTER_PROJECT_NAME>human lung metagenome</CENTER_PROJECT_NAME>
    </DESCRIPTOR>
  </STUDY>
</STUDY_SET>
